Jnana Therapeutics, 50 Northern Avenue, Boston 02210, USA.
Bioorg Med Chem. 2019 Aug 1;27(15):3451-3453. doi: 10.1016/j.bmc.2019.06.022. Epub 2019 Jun 13.
Chemogenomics expedites the discovery of therapeutically-relevant targets from phenotypic screens. However, the vast majority of proteins in the proteome lack selective pharmacological modulators, necessitating the development of new technologies that significantly expand chemogenomic space. Chemoproteomics has emerged as a robust platform to map small molecule-protein interactions in cells using functionalized chemical probes in conjunction with mass spectrometry analysis. Exploration of the ligandable proteome in this manner has led to the development of new pharmacological modulators of diverse proteins. Opportunities to further enhance the impact of chemoproteomics using medicinal chemical biology are described.
化学生物组学加快了从表型筛选中发现治疗相关靶点的速度。然而,蛋白质组中绝大多数蛋白质缺乏选择性的药理学调节剂,这就需要开发新技术,显著扩大化学生物组学的空间。化学生物组学已经成为一种强大的平台,可以使用功能化的化学探针结合质谱分析来绘制细胞中小分子-蛋白质相互作用。通过这种方式探索配体蛋白质组,已经开发出了针对多种蛋白质的新型药理学调节剂。本文描述了使用药物化学生物学进一步增强化学生物组学影响的机会。